Potentially transformative therapy for individuals with type 1 diabetes nearing major

[Northerner]

JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and ViaCyte, Inc., a leading regenerative medicine company, jointly announced that JDRF is providing additional milestone-based funding for the continued development of ViaCyte's VC-01? encapsulated cell therapy product candidate for the treatment of T1D. JDRF will fund up to $7 million to help ensure a rapid transition of the project into the clinical phase of development once ViaCyte's investigational new drug application (IND) is filed with and accepted by the U.S. Food and Drug Administration (FDA). This commitment builds on JDRF's previous support of ViaCyte's preclinical development program focused on collecting the necessary animal safety and efficacy data to support introduction into clinical testing.

http://www.sacbee.com/2014/02/06/6133609/jdrf-to-provide-additional-support.html

 

[Redkite]

Sounds very promising 🙂